- Class: PPIs (others = lansoprazole)
- Mode of action: irreversible inhibitor of H + K + ATPase pump at the secretory surface of gastric parietal cells. Inhibits final transport of hydrogen ions into gastric lumen; thereby inhibiting gastric acid secretion
- Indications: treatment of gastric and duodenal ulcers (peptic ulcer disease), prevention and treatment of NSAID-associated ulcers, Helicobacter pylori eradicaton (in combination with two antibiotics - Triple Therapy), GORD, Zollinger-Ellison syndrome
- Side effects: GI disturbance, e.g. nausea, vomiting, abdominal pain, flatulence, and headache
- Contra-indications: PPIs MAY MASK SYMPTOMS OF GASTRIC CANCER - in patients presenting with ‘alarm features’ (bleeding, dysphagia, recurrent vomiting, weight loss) it is important to rule out malignancy before commencing PPI therapy. Avoid in pregnancy and breast-feeding